Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Teva Pharmaceutical Industries ( TEVA) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.4%. By the end of trading, Teva Pharmaceutical Industries rose 89 cents (2.2%) to $41.31 on average volume. Throughout the day, 3.8 million shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 2.9 million shares. The stock ranged in a price between $40.51-$41.44 after having opened the day at $40.73 as compared to the previous trading day's close of $40.42. Other companies within the Drugs industry that increased today were: Novogen ( NVGN), up 32.7%, Prestige Brands Holdings ( PBH), up 18.5%, Savient Pharmaceuticals ( SVNT), up 17.9%, and China Pharma ( CPHI), up 13.5%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Teva Pharmaceutical Industries Limited develops, manufactures, and sells pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $35.06 billion and is part of the health care sector. The company has a P/E ratio of 10.9, below the S&P 500 P/E ratio of 17.7. Shares are up 0.1% year to date as of the close of trading on Wednesday. Currently there are 18 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and nine rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, attractive valuation levels and increase in net income. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall.

On the negative front, Pain Therapeutics ( PTIE), down 36.6%, Durect Corporation ( DRRX), down 33.6%, Biocryst Pharmaceuticals ( BCRX), down 12.4%, and Idera Pharmaceuticals ( IDRA), down 12.3%, were all laggards within the drugs industry with Novo Nordisk A/S ( NVO) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.
null